Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis

Türk, Süleyman; Karalezli, Giray; Tonbul, Halil Zeki; Yıldız, Mustafa; Altıntepe, Lütfullah; Yıldız, Alaattin; Yeksan, Mehdi

doi:10.1093/ndt/16.9.1818

Cited by 80 publications

(86 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 50% of uremic men complain of erectile dysfunction, while an even greater percentage of both men and women complain of decreased libido and a marked decline in the frequency of intercourse. [1,6] Soykan et al used the Arizona Sexual Experience Scale (ASEX) and reported that sexual dysfunction was 61% in female with HD patients. [5] Basok et al using FSFI scores reported that the rates of FSD were 81, 66.7, and 50% in the PD and HD patients and control subjects, respectively.…”

Section: Discussionmentioning

confidence: 99%

Female Sexual Dysfunction in Peritoneal Dialysis and Hemodialysis Patients

et al. 2009

Self Cite

View full text Add to dashboard Cite

Background. Sexual dysfunction (SD) is a common problem in end-stage renal disease (ESRD). In contrast to basic and clinical research in the field of male SD, the sexual problems of women have received relatively little attention and are often under-treated. We evaluated sexual function in female ESRD patients using the validated Female Sexual Function Index (FSFI) and relation with QOL, depression, and some laboratory parameters. Methods. 117 ESRD patients (85 peritoneal dialysis [PD], 32 hemodialysis [HD], mean age 48.5 ± 13.9 years) were enrolled. All patients had been dialyzed (PD or HD) for more than three months. In addition, an age-matched married control group of 48 subjects (mean age 47.1 ± 12.7 years) were enrolled in the study. All patients were asked to complete three questionnaires of the FSFI, Beck Depression Index (BDI) and SF-36. Results. Female sexual dysfunction was found in 80 of the 85 peritoneal dialysis patients (94.1%) and all of the HD patients (100%), but in only 22 subjects of the control group (45.8%). A significant negative correlation was found between total FSFI score and age (r = −0.288, p = 0.002), BDI score (r = −0.471, p < 0.001), mental-physical component score of QOL (r = −0.463, p < 0.001 and r = −0.491, p < 0.001, respectively) in PD and HD patients. The rates of depression were 75.3, 43.8, and 4.2% in the PD and HD patients and control subjects, respectively. Conclusion. Female sexual dysfunction is common problem ESRD. This problem especially related with depression and QOL. Thus, sexual function should be evaluated in female subjects to determine its impact on quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Female Sexual Dysfunction in Peritoneal Dialysis and Hemodialysis Patients

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…24,25 However, in HD patients studies report very high rates of ED of 71-80%. [1][2][3][4][5][6] Compared to non-uremic patients, the high rate of ED in HD patients has been identified as having organic and psychogenic causes. The successful treatment of ED in HD patients increases the quality of life and reduces psychometric factors in the ED etiology.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that the prevalence of ED is 71-80% in HD patients. [1][2][3][4][5][6] It has been found that organic and psychogenic factors are involved in severe increases in ED in HD patients compared to non-uremic patients. [7][8][9] In HD patients, there are increases in testicular failure, secondary disturbances in the pituitary-gonadal axis, plasma estrogen, and prolactin levels identified in the early period.…”

Section: Introductionmentioning

confidence: 99%

The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis

et al. 2016

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) is frequently observed in end-stage renal disease (ESRD) patients on hemodialysis (HD) compared to non-uremic patients. This situation causes severe psychogenic problems in patients and disrupts the quality of life. Different phosphodiesterase type 5 (PDE-5) inhibitors have been used, and efficacies revealed, for the treatment of ED in HD patients; however, there are no studies related to udenafil use or results for HD patients. This study retrospectively evaluated the efficacy and reliability of udenafil for HD patients. Materials and methods The laboratory findings, side effects after treatment, and International Index of Erectile Function (IIEF) scores before and after treatment were compared and evaluated for HD patients who applied to our urology clinic with ED complaints and were treated with udenafil. Results The results showed that in the HD patient group with ED, apart from ED, there were severe rates of other sexual dysfunction. In our patient group, there was a statistically significant improvement in all scores for erectile function (p ¼ 0.033), orgasmic function (p50.001), sexual desire (p50.001), relationship satisfaction (p50.001), and general satisfaction (p50.001) after treatment. The reported side effects were headache in one patient and dyspepsia in one patient. Conclusion We concluded that udenafil is an effective and reliable treatment approach for HD patients; however, our results require support from prospective randomized crossover studies with sildenafil.

show abstract

“…30 In chronic renal failure, 60% of patients with ED have a positive response to 50 or 100 mg of sildenafil. 31 This response rate is observed in both hemodialysis and ambulatory peritoneal dialysis patients. In all, 60% of renal transplant patients with ED who were treated with sildenafil reported an improvement in achieving and maintaining erections.…”

Section: S22mentioning

confidence: 92%

Specific aspects of erectile function in urology/andrology

et al. 2004

View full text Add to dashboard Cite

The urologist/andrologist is the specialist responsible for diagnosis and treatment of health problems related to the genitourinary tract, and his or her participation in comprehensive care for a patient with erectile dysfunction (ED) is fundamental and often indispensable. The urologists/ andrologists should characterize the origin of ED because of their knowledge and familiarity of all diagnostic tests and second-and third-line therapy. The origin of ED is important to determine for various reasons, such as young people suitable for etiologic treatment, medicolegal reasons, or patients' wishes for a better understanding of their condition. A review of the diagnostic tests available as well as indications for second-and third-line therapy is presented. The close relationship between ED and urological disorders, such as benign prostatic hyperplasia, prostate cancer and their treatments, and renal failure, in association with penile conditions like Peyronie's disease, priapism, and possible androgen deficiency in men older than 50 years, places the urologist at the center of integrated treatment of male ED.

show abstract

Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis

Cited by 80 publications

References 17 publications

Female Sexual Dysfunction in Peritoneal Dialysis and Hemodialysis Patients

Female Sexual Dysfunction in Peritoneal Dialysis and Hemodialysis Patients

The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis

Specific aspects of erectile function in urology/andrology

Contact Info

Product

Resources

About